These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36991394)

  • 61. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
    Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
    Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunization delivery in the second year of life in Ghana: the need for a multi-faceted approach.
    Nyaku M; Wardle M; Eng JV; Ametewee L; Bonsu G; Larbi Opare JK; Conklin L
    Pan Afr Med J; 2017; 27(Suppl 3):4. PubMed ID: 29296139
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessing the economic benefits of vaccines based on the health investment life course framework: a review of a broader approach to evaluate malaria vaccination.
    Constenla D
    Vaccine; 2015 Mar; 33(13):1527-40. PubMed ID: 25701316
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Assessing the Implementation Determinants of Pilot Malaria Vaccination Programs in Ghana, Kenya, and Malawi through a Complexity Lens: A Rapid Review Using a Consolidated Framework for Implementation Research.
    Adamu AA; Jalo RI; Ndwandwe D; Wiysonge CS
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400095
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cross-sectional health centre and community-based evaluation of the impact of pneumococcal and malaria vaccination on antibiotic prescription and usage, febrile illness and antimicrobial resistance in young children in Malawi: the IVAR study protocol.
    Singleton D; Ibarz-Pavon A; Swarthout TD; Bonomali F; Cornick J; Kalizang'oma A; Ntiza N; Brown C; Chipatala R; Nyangulu W; Chirombo J; Kawalazira G; Chibowa H; Mwansambo C; Maleta KM; French N; Heyderman RS
    BMJ Open; 2023 May; 13(5):e069560. PubMed ID: 37173105
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Willingness to accept malaria vaccine among caregivers of under-5 children in Ibadan North Local Government Area, Nigeria.
    Abdulkadir BI; Ajayi IO
    Malariaworld J; 2015; 6():2. PubMed ID: 38779629
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Optimising reporting of adverse events following immunisation by healthcare workers in Ghana: A qualitative study in four regions.
    Aborigo RA; Welaga P; Oduro A; Shaum A; Opare J; Dodoo A; Ampadu H; Gidudu JF
    PLoS One; 2022; 17(12):e0277197. PubMed ID: 36538549
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study.
    Thompson HA; Hogan AB; Walker PGT; Winskill P; Zongo I; Sagara I; Tinto H; Ouedraogo JB; Dicko A; Chandramohan D; Greenwood B; Cairns M; Ghani AC
    Lancet Glob Health; 2022 Dec; 10(12):e1782-e1792. PubMed ID: 36400084
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Facilitators and Barriers to Uptake of an Extended Seasonal Malaria Chemoprevention Programme in Ghana: A Qualitative Study of Caregivers and Community Health Workers.
    Antwi GD; Bates LA; King R; Mahama PR; Tagbor H; Cairns M; Newell JN
    PLoS One; 2016; 11(11):e0166951. PubMed ID: 27898699
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
    Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M
    Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost of introducing and delivering malaria vaccine (RTS,S/AS01
    Diawara H; Bocoum FY; Dicko A; Levin A; Lee C; Koita F; Ouédraogo JB; Guissou R; Yabré S; Traoré S; Morgan W; Pecenka C; Baral R
    BMJ Glob Health; 2023 Apr; 8(4):. PubMed ID: 37068848
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria.
    Wilby KJ; Lau TT; Gilchrist SE; Ensom MH
    Ann Pharmacother; 2012 Mar; 46(3):384-93. PubMed ID: 22408046
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Successful implementation of ITN distribution through health facilities in Ghana.
    Nuñez L; Skjefte M; Asamoah OE; Owusu P; Malm K; Miller JE
    Malar J; 2023 Aug; 22(1):224. PubMed ID: 37533014
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure.
    Kurtovic L; Agius PA; Feng G; Drew DR; Ubillos I; Sacarlal J; Aponte JJ; Fowkes FJI; Dobaño C; Beeson JG
    BMC Med; 2019 Feb; 17(1):45. PubMed ID: 30798787
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Healthcare workers' perceptions and experiences of communicating with people over 50 years of age about vaccination: a qualitative evidence synthesis.
    Glenton C; Carlsen B; Lewin S; Wennekes MD; Winje BA; Eilers R;
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013706. PubMed ID: 34282603
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Examining enablers of vaccine hesitancy toward routine childhood and adolescent vaccination in Malawi.
    Adeyanju GC; Betsch C; Adamu AA; Gumbi KS; Head MG; Aplogan A; Tall H; Essoh TA
    Glob Health Res Policy; 2022 Aug; 7(1):28. PubMed ID: 35978401
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Caregiver and community perceptions and experiences participating in an infant malaria prevention trial of PfSPZ Vaccine administered by direct venous inoculation: a qualitative study in Siaya County, western Kenya.
    Achieng F; Rosen JG; Cherop RY; Kariuki S; Hoffman SL; Seder R; Oneko M; Steinhardt LC
    Malar J; 2020 Jun; 19(1):226. PubMed ID: 32580719
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of health system readiness and coverage of intermittent preventive treatment of malaria in infants (IPTi) in Kambia district to inform national scale-up in Sierra Leone.
    Lahuerta M; Sutton R; Mansaray A; Eleeza O; Gleason B; Akinjeji A; Jalloh MF; Toure M; Kassa G; Meshnick SR; Deutsch-Feldman M; Parmley L; Friedman M; Smith SJ; Rabkin M; Steinhardt L
    Malar J; 2021 Feb; 20(1):74. PubMed ID: 33549098
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
    RTS,S Clinical Trials Partnership
    PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.